Pregabalin + placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Post Herpetic Neuralgia
Conditions
Post Herpetic Neuralgia
Trial Timeline
Mar 1, 2011 → Nov 1, 2014
NCT ID
NCT01270828About Pregabalin + placebo
Pregabalin + placebo is a phase 3 stage product being developed by Pfizer for Post Herpetic Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT01270828. Target conditions include Post Herpetic Neuralgia.
What happened to similar drugs?
20 of 20 similar drugs in Post Herpetic Neuralgia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03407430 | Phase 2 | Terminated |
| NCT02607254 | Phase 2 | Completed |
| NCT01701362 | Phase 3 | Completed |
| NCT01387607 | Phase 3 | Completed |
| NCT01455415 | Phase 3 | Completed |
| NCT01432236 | Phase 3 | Completed |
| NCT01271660 | Phase 3 | Completed |
| NCT01271933 | Phase 3 | Completed |
| NCT01270828 | Phase 3 | Completed |
| NCT01049217 | Phase 3 | Terminated |
| NCT00977197 | Phase 2 | Completed |
| NCT00883740 | Phase 3 | Completed |
| NCT00762099 | Approved | UNKNOWN |
| NCT00852436 | Phase 2 | Terminated |
| NCT00994786 | Approved | Completed |
| NCT00631696 | Approved | Completed |
| NCT00584376 | Approved | Completed |
| NCT00380874 | Approved | Terminated |
| NCT00381095 | Approved | Terminated |
| NCT00413010 | Phase 3 | Completed |
Competing Products
20 competing products in Post Herpetic Neuralgia